Clinical Trial Update: Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis [Phase 2, Phase 3]

View source ↗

Summary

Open-label extension study of nalbuphine HCl ER in patients with prurigo nodularis has completed, with results posted in October 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prurigo Nodularis

Drugs mentioned

• Nalbuphine HCl ER (nalbuphine hydrochloride extended-release)

Snippet

Sponsor: Trevi Therapeutics | Conditions: Prurigo Nodularis, Nodularis Prurigo | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2020-10-23